USRM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
USRM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
US Stem Cell's yield on cost for the quarter that ended in Dec. 2022 was 0.00.
The historical rank and industry rank for US Stem Cell's 5-Year Yield-on-Cost % or its related term are showing as below:
For the Biotechnology subindustry, US Stem Cell's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, US Stem Cell's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where US Stem Cell's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of US Stem Cell is calculated as
Yield-on-Cost | = | Dividend Yield % | * | (1 | + | Dividend Growth Rate)^5 |
US Stem Cell (OTCPK:USRM) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Thank you for viewing the detailed overview of US Stem Cell's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.
Murphy William P Jr | director | 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325 |
Gregory Knutson | director | 14855 ABERDEN STREET NE, HAM LAKE MN 55304 |
Mark P Borman | director | 5240 WASHBURN AVENUE SOUTH, MINNEAPOLIS MN 55410 |
Charles A Hart | director | 19345 RHINESTONE STREET NW, ANOKA MN 55303 |
Sheldon T. Anderson | director | 1121 CRANDON BLVD., APT. D-103, KEY BISCAYNE FL 33149 |
Kristin C Comella | officer: Chief Science Officer | 1310 LEEWARD WAY, WESTON FL 33327 |
A Jones Lee | director | 54 LOCKE LAKE RD, FRIDLEY MN 55432 |
Karl Groth | director | 1160 FIFTH AVENUE, SUITE 207, NEW YORK NY 10029 |
Matthew J Fendrich | officer: Vice President,Sales&Marketing | 482 PEACOCK LANE SOUTH, JUPITER FL 33458 |
Alan P Timmins | director | 1111 MAIN STREET, SUITE 600, VANCOUVER WA 98660 |
Bruce C Carson | director | 11850 COTTONWOOD STREET NW, COON RAPIDS MN 55448 |
Howard J Leonhardt | director, 10 percent owner, officer: Executive Chairman & CTO | 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325 |
Bromley R Scott | officer: VP of Public Relations | 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325 |
Richard Iii Spencer | director | 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325 |
Mike Tomas | director | 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325 |
From GuruFocus
By PRNewswire PRNewswire • 06-01-2018
By PRNewswire PRNewswire • 05-15-2018
By ACCESSWIRE ACCESSWIRE • 02-23-2021
By PRNewswire PRNewswire • 09-11-2018
By PRNewswire PRNewswire • 05-08-2018
By PRNewswire PRNewswire • 09-26-2018
By PRNewswire PRNewswire • 05-17-2018
By PRNewswire PRNewswire • 05-08-2019
By ACCESSWIRE ACCESSWIRE • 03-09-2022
By PRNewswire PRNewswire • 08-10-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.